April 24, 2019 / 3:30 PM / 3 months ago

BRIEF-Novartis says 'vast majority' of Lutathera sales in U.S.

April 24 (Reuters) - Novartis AG:

* SAYS "VAST MAJORITY" OF RADIOLIGAND THERAPY LUTATHERA'S $106 MILLION Q1 SALES CAME FROM UNITED STATES

* CEO SAYS DELAYED BULK OF 2019 SHARE BUYBACK UNTIL AFTER ALCON SPIN-OFF, TO MAXIMIZE NUMBER OF NOVARTIS SHARES TAKEN OUT OF CIRCULATION

* CANCER HEAD SAYS FDA HAS NOT YET APPROVED SUPPLEMENTAL APPLICATION TO BROADEN KYMRIAH'S COMMERCIAL SPECIFICATION, CITING INSUFFICIENT INFORMATION

* CANCER HEAD SAYS DISAPPOINTED BY FDA DECISION ON KYMRIAH, WORKING CLOSELY TO FIND A PATH FORWARD AS WELL AS COLLECTING ADDITIONAL DATA Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below